Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
ArriVent's FURVENT Phase 3 trial misses PFS endpoint in EGFR exon 20 NSCLCOct 6Clinical readoutArriVent BioPharma, Inc.firmonertinib
ArriVent reports Q2 2026 results, licenses ARR-002 to Allist in Greater ChinaAug 12Quarterly updateARR-002ArriVent BioPharma, Inc.